Alkem Laboratories quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	3,740	3,371	+10.9%
EBITDA	766	739	+3.7%
EBITDA margin	20.5%	21.9%	−1.4 pts
Profit before tax	772	771	+0.1%
Net profit	521	668	−22.0%
EPS	₹43.49	₹55.56	−21.7%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	3,740	3,603	3,737	4,001	3,371	3,144	3,374	3,415	3,032	2,936	3,324	3,440	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	153	200	143	104	136	146	93.0	134	120	88.2	93.6	63.2
	3,893	3,803	3,880	4,105	3,508	3,290	3,467	3,549	3,152	3,024	3,418	3,503
	910	895	938	906	827	777	924	902	837	799	839	825
	366	498	328	472	397	380	397	354	383	381	461	432
	−74.7	−145	7.0	23.9	−53.2	122	−117	−51.4	−144	−72.1	5.2	70.5
	809	712	722	710	693	616	625	610	602	506	572	555
	46.6	53.9	42.1	35.0	29.8	28.4	36.0	28.1	29.1	26.9	25.5	30.3
	100	106	95.0	93.6	87.7	112	85.3	78.9	80.5	83.4	69.6	73.9
	964	1,126	915	969	768	857	786	847	745	921	740	811
	3,121	3,246	3,046	3,209	2,750	2,893	2,736	2,769	2,533	2,644	2,711	2,798
	766	517	828	921	739	391	759	753	609	402	708	747
	666	412	733	827	651	279	674	674	528	319	638	673
Profit
	772	558	834	896	758	396	731	780	619	380	706	706
	0.0	−135	−52.8	0.0	12.9	0.0	0.0	0.0	0.0	−12.5	−51.3	−57.7
	772	423	781	896	771	396	731	780	619	367	655	648
	232	122	177	180	141	84.3	159	156	124	83.9	114	159
	18.4	49.5	−49.3	−63.7	−38.4	−10.9	−68.8	−77.6	−55.3	−21.0	−63.0	−126
	251	171	128	116	103	73.3	90.3	78.3	69.1	62.9	50.6	33.2
	−0.5	−0.6	−0.5	−0.5	−0.4	−0.6	0.0	0.0	0.0	0.0	0.0	0.0
	521	251	653	779	668	322	641	702	550	304	604	615
	521	252	654	780	668	323	641	702	550	304	604	615
	2.9	115	23.6	42.9	2.1	−2.6	12.1	6.1	4.1	−7.7	5.5	11.0
	524	366	677	822	670	320	653	708	554	297	610	626
	520	236	636	765	664	306	626	689	545	294	595	621
	1.0	14.7	17.0	14.1	3.7	16.5	15.0	13.3	5.1	10.9	9.3	−5.6
Per share
	₹43.49	₹19.77	₹53.19	₹63.99	₹55.56	₹25.57	₹52.34	₹57.60	₹45.60	₹24.55	₹49.76	₹51.90
	₹43.49	₹19.77	₹53.19	₹63.99	₹55.56	₹25.57	₹52.34	₹57.60	₹45.60	₹24.55	₹49.76	₹51.90
Other comprehensive income — detail
	2.9	115	23.6	42.9	2.1	−2.6	—	—	—	—	—	—
	−2.5	35.5	−14.1	−4.5	−4.8	−6.4	−3.8	−6.6	−5.0	0.2	−2.6	−3.0
	−0.8	11.8	−5.1	−2.7	−0.3	−2.2	—	—	—	—	—	—
	—	—	—	—	—	—	−1.3	−2.1	−1.6	0.2	−0.8	−1.1
	4.6	91.7	32.6	44.7	6.6	1.7	14.6	10.6	7.5	−7.7	7.3	12.9
	523	350	660	808	667	303	638	695	550	286	600	632
	1.0	16.6	17.1	13.7	3.4	16.5	15.0	12.6	4.8	11.0	9.3	−5.8
Per share — as-filed variants
	₹43.49	₹19.77	₹53.19	₹63.99	₹55.56	₹25.57	₹52.34	₹57.60	₹45.60	₹24.55	₹49.76	₹51.90
	₹43.49	₹19.77	₹53.19	₹63.99	₹55.56	₹25.57	₹52.34	₹57.60	₹45.60	₹24.55	₹49.76	₹51.90
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,539	2,355	2,464	2,600	2,200	1,864	2,170	2,210	1,956	1,828	2,019	2,113
	67.9%	65.4%	65.9%	65.0%	65.3%	59.3%	64.3%	64.7%	64.5%	62.3%	60.8%	61.4%
Adjusted (ex-exceptional items) — derived
	772	558	834	896	758	396	731	780	619	380	706	706
	0.0	−135	−52.8	0.0	12.9	0.0	0.0	0.0	0.0	−12.5	−51.3	−57.7
	521	331	697	779	657	322	641	702	550	315	652	670
	₹43.49	₹26.09	₹56.79	₹63.99	₹54.63	₹25.57	₹52.34	₹57.60	₹45.60	₹25.39	₹53.66	₹56.52

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALKEM₹5,079.00

Alkem Laboratories Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersMANKIND TORNTPHARM IPCALAB LUPIN FORTIS AUROPHARMA LAURUSLABS BIOCONMcap ₹60,719 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	3,440.2	3,323.9	2,935.8	3,031.8	3,414.7	3,374.3	3,143.8	3,371.1	4,001.0	3,736.8	3,603.3	3,740.2
Other Income	63.2	93.6	88.2	120.3	134.5	93.0	146.0	136.5	103.7	143.1	200.1	152.8
Total Income	3,503.4	3,417.5	3,024.0	3,152.1	3,549.2	3,467.3	3,289.7	3,507.6	4,104.7	3,879.9	3,803.4	3,892.9
Expenses
+ Cost of Materials Consumed	824.7	838.5	798.8	837.2	902.2	924.0	777.0	827.1	905.6	937.8	894.9	910.0
+ Purchases of Stock-in-Trade	431.9	460.8	380.7	382.7	353.9	397.5	380.0	397.2	471.6	328.0	497.8	366.0
+ Changes in Inventories	70.5	5.2	-72.1	-143.9	-51.4	-117.2	122.3	-53.2	23.9	7.0	-144.8	-74.7
+ Employee Benefit Expense	555.4	572.2	505.8	602.3	610.5	624.8	616.4	693.3	710.3	721.5	712.1	808.9
+ Finance Costs	30.3	25.5	26.9	29.1	28.1	36.0	28.4	29.8	35.0	42.1	53.9	46.6
+ Depreciation & Amortisation	73.9	69.6	83.4	80.5	78.9	85.3	112.5	87.7	93.6	95.0	105.8	100.2
+ Other Expenses	811.0	739.6	920.6	745.0	846.7	785.8	856.8	767.7	968.9	914.6	1,126.0	963.9
Total Expenses	2,797.7	2,711.3	2,644.1	2,532.8	2,768.9	2,736.2	2,893.4	2,749.6	3,208.9	3,045.9	3,245.6	3,120.9
EBITDA	746.7	707.6	402.0	608.6	752.8	759.4	391.3	739.1	920.8	828.0	517.4	766.1
EBIT	672.8	638.0	318.6	528.2	673.9	674.1	278.8	651.4	827.2	733.0	411.6	665.9
Profit
PBT before Exceptional Items	705.7	706.2	379.9	619.4	780.3	731.1	396.3	758.1	895.8	834.0	557.8	772.0
+ Exceptional Items	-57.7	-51.3	-12.5	0.0	0.0	0.0	0.0	12.9	0.0	-52.8	-135.0	0.0
Pretax Income	648.0	654.9	367.3	619.4	780.3	731.1	396.3	771.0	895.8	781.2	422.9	772.0
+ Current Tax	159.1	113.6	83.9	124.4	155.9	159.0	84.3	141.1	180.0	177.0	121.6	232.1
+ Deferred Tax	-125.9	-63.0	-21.0	-55.3	-77.6	-68.8	-10.9	-38.4	-63.7	-49.3	49.5	18.4
Tax Expense	33.2	50.6	62.9	69.1	78.3	90.3	73.3	102.7	116.2	127.7	171.2	250.5
+ Share of Associates & JVs	0.0	0.0	0.0	0.0	0.0	0.0	-0.6	-0.4	-0.5	-0.5	-0.6	-0.5
Net Income	614.9	604.3	304.5	550.2	702.0	640.8	322.4	667.9	779.1	653.0	251.1	521.0
+ Net Income — Continuing Ops	614.9	604.3	304.5	550.2	702.0	640.8	323.0	668.3	779.6	653.5	251.7	521.5
+ Other Comprehensive Income	11.0	5.5	-7.7	4.1	6.1	12.1	-2.6	2.1	42.9	23.6	115.3	2.9
Total Comprehensive Income	625.9	609.8	296.8	554.4	708.1	652.9	319.8	670.0	822.0	676.6	366.4	523.9
Net Income to Common	620.5	595.0	293.6	545.2	688.6	625.8	305.9	664.3	765.1	636.0	236.5	520.0
Minority Interest	-5.6	9.3	10.9	5.1	13.3	15.0	16.5	3.7	14.1	17.0	14.7	1.0
Per Share
Basic EPS	51.90	49.76	24.55	45.60	57.60	52.34	25.57	55.56	63.99	53.19	19.77	43.49
Diluted EPS	51.90	49.76	24.55	45.60	57.60	52.34	25.57	55.56	63.99	53.19	19.77	43.49
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-2.6	2.1	42.9	23.6	115.3	2.9
+ Items NOT to be Reclassified to P&L	-3.0	-2.6	0.2	-5.0	-6.6	-3.8	-6.4	-4.8	-4.5	-14.1	35.5	-2.5
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-2.2	-0.3	-2.7	-5.1	11.8	-0.8
+ Tax on Items NOT to be Reclassified — alt tag	-1.1	-0.8	0.2	-1.6	-2.1	-1.3	—	—	—	—	—	—
+ Items to be Reclassified to P&L	12.9	7.3	-7.7	7.5	10.6	14.6	1.7	6.6	44.7	32.6	91.7	4.6
Comprehensive Income — Owners of Parent	631.7	600.4	285.9	549.6	695.5	637.9	303.3	666.6	808.3	659.5	349.8	522.9
Comprehensive Income — Non-controlling Interests	-5.8	9.3	11.0	4.8	12.6	15.0	16.5	3.4	13.7	17.1	16.6	1.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	51.90	49.76	24.55	45.60	57.60	52.34	25.57	55.56	63.99	53.19	19.77	43.49
Diluted EPS — Continuing Operations	51.90	49.76	24.55	45.60	57.60	52.34	25.57	55.56	63.99	53.19	19.77	43.49
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,113.1	2,019.3	1,828.4	1,955.9	2,210.0	2,170.0	1,864.5	2,200.0	2,600.0	2,464.1	2,355.5	2,538.9
Gross Margin %	61.42	60.75	62.28	64.51	64.72	64.31	59.31	65.26	64.98	65.94	65.37	67.88
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	705.7	706.2	379.9	619.4	780.3	731.1	396.3	758.1	895.8	834.0	557.8	772.0
− Exceptional Items (reconciliation)	-57.7	-51.3	-12.5	0.0	0.0	0.0	0.0	12.9	0.0	-52.8	-135.0	0.0
Net Income Adj (tax-effected)	669.6	651.6	314.9	550.2	702.0	640.8	322.4	656.7	779.1	697.2	331.4	521.0
EPS Adj	56.52	53.66	25.39	45.60	57.60	52.34	25.57	54.63	63.99	56.79	26.09	43.49
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	23.9	23.9	23.9	23.9	23.9	23.9	23.9	23.9	23.9	23.9	23.9	23.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Alkem Laboratories quarterly results

Alkem Laboratories (NSE: ALKEM) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹520 crore, down 21.7% from ₹664 crore in Q1 FY26 and up 119.9% from ₹236 crore in Q4 FY26. Revenue from operations was ₹3,740 crore, up 10.9% year on year and up 3.8% from the previous quarter.

Q2 FY26 results (a year earlier): 13 November 2025

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹520 Cr−21.7% vs Q1 FY26+119.9% vs Q4 FY26
Q1 FY27 revenue: ₹3,740 Cr+10.9% vs Q1 FY26+3.8% vs Q4 FY26
Q1 FY27 operating margin: 17.8%−1.5 pts vs Q1 FY26+6.4 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹765 CrRevenue ₹4,001 Cr
Q1 FY27 EPS (basic): ₹43.49

Questions

When will Alkem Laboratories announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 13 November 2025.

What will Alkem Laboratories' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹765 crore and revenue from operations ₹4,001 crore. The latest quarter, Q1 FY27, had a net profit of ₹520 crore and revenue of ₹3,740 crore.

What were Alkem Laboratories' Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹520 crore, down 21.7% from ₹664 crore in Q1 FY26 and up 119.9% from ₹236 crore in Q4 FY26. Revenue from operations was ₹3,740 crore, up 10.9% year on year and up 3.8% from the previous quarter.

How has Alkem Laboratories' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹765 crore in Q2 FY26, ₹636 crore in Q3 FY26, ₹236 crore in Q4 FY26 and ₹520 crore in Q1 FY27. That is ₹2,158 crore over the four quarters, down 5.6% from ₹2,285 crore in the four quarters before. Revenue from operations: ₹4,001 crore, ₹3,737 crore, ₹3,603 crore and ₹3,740 crore.

What was Alkem Laboratories' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹2,302 crore in FY26 (April 2025–March 2026), up 6.3% from ₹2,165 crore in FY25. It was ₹1,796 crore in FY24 and ₹984 crore in FY23: up 133.9% over three years, 32.7% a year on average.

What was Alkem Laboratories' revenue in FY26?

Revenue from operations was ₹14,712 crore in FY26 (April 2025–March 2026), up 13.5% from ₹12,965 crore in FY25. It was ₹12,668 crore in FY24 and ₹11,599 crore in FY23: up 26.8% over three years, 8.2% a year on average.

Where do these Alkem Laboratories figures come from?

From Alkem Laboratories' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.